# US 10,052,376 B2 · Laser-based vaccine adjuvants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,052,376 B2
- Document ID: US10052376B2
- Status: Granted
- Kind: B2
- Application number: 14/255,931
- Filed: 2014-04-17
- Published: 2014-11-13
- Granted: 2018-08-21
- Earliest claimed: 2008-10-06
- Assignees: Alternative Innovative Technologies LLC
- Applicants: Sergey B. Onikienko; Alexander V. Zemlyanoi; Boris A. Margulis; Irina V. Guzhova; Anna A. Pimenova
- Inventors: Sergey B. Onikienko; Alexander V. Zemlyanoi; Boris A. Margulis; Irina V. Guzhova; Anna A. Pimenova
- Web page: https://patentgrep.com/patent/US10052376B2

## CPC

- A61K 39/29: Hepatitis virus
- A61K 39/095: Neisseria
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61N 5/0613: {Apparatus adapted for a specific treatment}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55516: {Proteins; Peptides}
- A61N 5/067: using laser light
- A61N 2005/0659: {infrared}
- A61N 2005/0662: {Visible light}
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine.

## Claims

### Claim 1

A method of generating an enhanced immune response in a subject comprising administering a vaccine composition to a subject via intradermal, subcutaneous, and intramuscular injection in combination with non-destructive laser radiation, wherein the laser radiation is administered to the subject within an hour of the vaccine administration to the subject, thereby generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation, wherein the vaccine composition further comprises HSP 70.

### Claim 2 (depends on 1)

The method of claim 1, wherein the enhanced immune response is generated from a non-responsive subject.

### Claim 3 (depends on 1)

The method of claim 1, to generate the enhanced immune response from the subject with an increased HSP 70 concentration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the non-destructive laser radiation has of a frequency of the laser is about 1 to about 20 kilohertz, a power of the laser is about 1 to about 10 watts, and a pulse duration is about 1 to about 1000 nanoseconds.

### Claim 5 (depends on 1)

The method of claim 1, wherein the previous exposure to the non-destructive laser radiation was of a wavelength of 510 nm and 578 nm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the previous exposure to the non-destructive laser radiation was from a neodymium-doped yttrium aluminum garnet (Nd:YAG) laser.

### Claim 7 (depends on 1)

The method of claim 1, wherein the enhanced immune response comprises an increase in an antibody titer specific to the vaccine.

### Claim 8 (depends on 1)

The method of claim 1, wherein the enhanced immune response comprises an increased resistance to a condition characterized by a decrease in infection rate upon exposure to a pathogen specific to the vaccine, a decrease in mortality in response to exposure to a pathogen specific to the vaccine, or a decrease in time to detect a response to the vaccine.

### Claim 9 (depends on 1)

The method of claim 1, wherein the laser radiation is administered either before or after administration of the vaccine to the subject.